유전자 재조합 인간 부갑상선호르몬(1-34)으로 회복된 비스포스포네이트 연관 악골 괴사 증례
A Case of Intractable Bisphosphonate-Related Osteonecrosis of the Jaw Treated with Teriparatide
1
조회
0
다운로드
0
인용
0
참고문헌
키워드
초록
Bisphosphonates are the most widely used medications for treating high bone turnover osteoporosis, Paget`s disease of bone, multiple myeloma and metastatic carcinomas, etc. However, a destructive complication of bisphosphonate-related osteonecrosis of the jaw (BRONJ) can occur. The treatments of BRONJ are challenging and the currently recommended managements for BRONJ are still controversial. Our case demonstrated that teriparatide can be a treatment of choice for intractable BRONJ, which had not been cured for 2 years even with the proper surgical treatment and withdrawal of bisphosphonates.
Abstract
Bisphosphonates are the most widely used medications for treating high bone turnover osteoporosis, Paget`s disease of bone, multiple myeloma and metastatic carcinomas, etc. However, a destructive complication of bisphosphonate-related osteonecrosis of the jaw (BRONJ) can occur. The treatments of BRONJ are challenging and the currently recommended managements for BRONJ are still controversial. Our case demonstrated that teriparatide can be a treatment of choice for intractable BRONJ, which had not been cured for 2 years even with the proper surgical treatment and withdrawal of bisphosphonates.
참고문헌 (18)
- Marx RE, "Pamidronate (Aredia) and zoledronate(Zometa) induced avascular necrosis of the jaws: agrowing epidemic", J Oral Maxillofac Surg, 61, pp.1115~1117 (2003)
- Ruggiero SL, "Bisphosphonate-related osteonecrosis of the jaw: diagnosis, prevention, and management", Annu Rev Med, 60, pp.85~96 (2009)
- Ruggiero SL, "Osteonecrosis of the jaws associated with the use of bisphosphonates: a review of 63 cases", J Oral Maxillofac Surg, 62, pp.527~534 (2004)
- 정윤석, "비스포스포네이트와 연관된 악골 괴사의 임상 양상", OSTEOPOROSIS, 8(1), pp.73~81 (2010), 대한골다공증학회
- "J Oral Maxillofac Surg", 2007, 573~580
- Kwon YD, "Short-term teriparatide therapy as an adjunctive modality for bisphosphonate-related osteonecrosis of the jaws", Osteoporos Int (2012)
- Lee JJ, "Successful treatment of advanced bisphosphonaterelated osteonecrosis of the mandible with adjunctive teriparatide therapy", Head Neck, 33, pp.1366~1371 (2011)
- Freiberger JJ, "Utility of hyperbaric oxygen in treatment of bisphosphonate-related osteonecrosis of the jaws", J Oral Maxillofac Surg, 67, pp.96~106 (2009)
- improves both cortical and cancellous bone structure, "J Bone Miner Res", 2003, 1932~1941
- Grey A, "Teriparatide for bone loss in the jaw", N Engl J Med, 363, pp.2458~2459 (2010)
- Neer RM, "Effect of parathy roid hormone (1-34) on fractures and bone mineral density in postmenopausal women with osteoporosis", N Engl J Med, 344, pp.1434~1441 (2001)
- Black DM, "Randomized trial of once-weekly parathyroid hormone (1-84) on bone mineral density and remodeling", Clin Endocrinol Metab, 93, pp.2166~2172 (2008)
- 최성욱, "골다공증 환자에서 경구 비스포스포네이트 치료 중 발생한 악골 괴사", 대한정형외과학회지, 45(2), pp.151~154 (2010), 대한정형외과학회
- 이정근, "A probable case of oral bisphosphonate-associated osteonecrosis of the jaw and recovery with parathyroid hormone treatment", Current Therapeutic Research - Clinical and Experimental, 69(4), pp.356~362, Excerpta Medica, Inc.
- de Souza Faloni AP, "Accurate approach in the treatment of oral bisphosphonaterelated jaw osteonecrosis", J Craniofac Surg, 22, pp.2185~2190 (2011)
- Mavrokokki T, "Nature and frequency of bisphosphonate-associated osteonecrosis of the jaws in Australia", J Oral Maxillofac Surg, 65, pp.415~423 (2007)
- Rhee Y, "Maintenance of increased bone mass after recombinant human parathyroid hormone (1-84) with sequential zoledronate treatment in ovariectomized rats", J Bone Miner Res, 19, pp.931~937 (2004)
- Kurland ES, "The importance of bisphosphonate therapy in maintaining bone mass in men after therapy with teriparatide [human parathyroid hormone(1-34)", Osteoporos Int, 15, pp.992~997 (2004)